Cumberland shares DMD and cancer trial data, closes Apotex sale in Q2 update
Cumberland Pharmaceuticals reported new Phase 2 results for ifetroban in Duchenne muscular dystrophy and cancer metastasis prevention alongside second-quarter 2026 results following its $100 million Apotex transaction.
SEC filing